Prof. Dr. Eugen Leo


Eugen is Chief Medical Officer at T-knife. He has over 20 years of experience in Phase I and II development of targeted molecules (kinase inhibitors, antibodies, antibody derivatives, vaccines, and antisense molecules) with a strong focus on immuno-oncology. Previously, he held CMO/Medical Lead positions in biotech (e.g. Rigontec (acquired by Merck Inc. in 2017) and Micromet (acquired by Amgen in 2012)) and large pharmaceutical companies (Merck-Serono, Johnson&Johnson). He is a board-certified Hematologist, Medical Oncologist and Associate Professor of Medicine and did his postdoc/research fellowship at the Sanford-Burnham-Prebys Institute, La Jolla, CA (USA). He studied Medicine at Freiburg University and holds an MBA from Colorado State University (USA) and currently also serves as CMO of Catalym/Munich.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.